NZ626979A - Mice expressing a light chain with human lambda variable and mouse constant regions - Google Patents

Mice expressing a light chain with human lambda variable and mouse constant regions

Info

Publication number
NZ626979A
NZ626979A NZ626979A NZ62697911A NZ626979A NZ 626979 A NZ626979 A NZ 626979A NZ 626979 A NZ626979 A NZ 626979A NZ 62697911 A NZ62697911 A NZ 62697911A NZ 626979 A NZ626979 A NZ 626979A
Authority
NZ
New Zealand
Prior art keywords
light chain
constant regions
mice expressing
mouse constant
human lambda
Prior art date
Application number
NZ626979A
Other languages
English (en)
Inventor
Lynn Macdonald
Sean Stevens
Cagan Gurer
Andrew J Murphy
Karolina A Hosiawa
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority to NZ707198A priority Critical patent/NZ707198A/en
Publication of NZ626979A publication Critical patent/NZ626979A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Position Input By Displaying (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
NZ626979A 2010-06-22 2011-06-22 Mice expressing a light chain with human lambda variable and mouse constant regions NZ626979A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ707198A NZ707198A (en) 2010-06-22 2011-06-22 Mice expressing a light chain with human lambda variable and mouse constant regions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35731410P 2010-06-22 2010-06-22
US35731710P 2010-06-22 2010-06-22
NZ605751A NZ605751A (en) 2010-06-22 2011-06-22 Mice expressing a light chain with human lambda variable and mouse constant regions

Publications (1)

Publication Number Publication Date
NZ626979A true NZ626979A (en) 2015-05-29

Family

ID=44509861

Family Applications (6)

Application Number Title Priority Date Filing Date
NZ626979A NZ626979A (en) 2010-06-22 2011-06-22 Mice expressing a light chain with human lambda variable and mouse constant regions
NZ707198A NZ707198A (en) 2010-06-22 2011-06-22 Mice expressing a light chain with human lambda variable and mouse constant regions
NZ627119A NZ627119A (en) 2010-06-22 2011-06-22 Hybrid light chain mice
NZ605758A NZ605758A (en) 2010-06-22 2011-06-22 Hybrid light chain mice
NZ707200A NZ707200A (en) 2010-06-22 2011-06-22 Hybrid light chain mice
NZ605751A NZ605751A (en) 2010-06-22 2011-06-22 Mice expressing a light chain with human lambda variable and mouse constant regions

Family Applications After (5)

Application Number Title Priority Date Filing Date
NZ707198A NZ707198A (en) 2010-06-22 2011-06-22 Mice expressing a light chain with human lambda variable and mouse constant regions
NZ627119A NZ627119A (en) 2010-06-22 2011-06-22 Hybrid light chain mice
NZ605758A NZ605758A (en) 2010-06-22 2011-06-22 Hybrid light chain mice
NZ707200A NZ707200A (en) 2010-06-22 2011-06-22 Hybrid light chain mice
NZ605751A NZ605751A (en) 2010-06-22 2011-06-22 Mice expressing a light chain with human lambda variable and mouse constant regions

Country Status (30)

Country Link
US (22) US9012717B2 (cg-RX-API-DMAC7.html)
EP (7) EP2568049B1 (cg-RX-API-DMAC7.html)
JP (16) JP5988969B2 (cg-RX-API-DMAC7.html)
KR (16) KR102001430B1 (cg-RX-API-DMAC7.html)
CN (4) CN104404050B (cg-RX-API-DMAC7.html)
AU (1) AU2011271046B2 (cg-RX-API-DMAC7.html)
BR (3) BR112012033248A2 (cg-RX-API-DMAC7.html)
CA (2) CA2804311C (cg-RX-API-DMAC7.html)
CY (5) CY1117537T1 (cg-RX-API-DMAC7.html)
DK (5) DK3034608T3 (cg-RX-API-DMAC7.html)
ES (5) ES2576928T3 (cg-RX-API-DMAC7.html)
HR (5) HRP20160794T1 (cg-RX-API-DMAC7.html)
HU (5) HUE036597T2 (cg-RX-API-DMAC7.html)
IL (12) IL313063A (cg-RX-API-DMAC7.html)
LT (4) LT2568049T (cg-RX-API-DMAC7.html)
ME (5) ME03386B (cg-RX-API-DMAC7.html)
MX (6) MX336344B (cg-RX-API-DMAC7.html)
MY (6) MY194456A (cg-RX-API-DMAC7.html)
NO (1) NO2905338T3 (cg-RX-API-DMAC7.html)
NZ (6) NZ626979A (cg-RX-API-DMAC7.html)
PL (5) PL2905338T3 (cg-RX-API-DMAC7.html)
PT (5) PT2480676E (cg-RX-API-DMAC7.html)
RS (5) RS55037B1 (cg-RX-API-DMAC7.html)
RU (3) RU2590594C2 (cg-RX-API-DMAC7.html)
SG (4) SG10201504568YA (cg-RX-API-DMAC7.html)
SI (5) SI2568049T1 (cg-RX-API-DMAC7.html)
SM (5) SMT201900241T1 (cg-RX-API-DMAC7.html)
TR (1) TR201905992T4 (cg-RX-API-DMAC7.html)
WO (2) WO2011163311A1 (cg-RX-API-DMAC7.html)
ZA (5) ZA201300063B (cg-RX-API-DMAC7.html)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK2346994T3 (da) 2008-09-30 2022-02-28 Ablexis Llc Knock-in-mus til fremstilling af kimære antistoffer
RU2011129459A (ru) 2008-12-18 2013-01-27 Эрасмус Юниверсити Медикал Сентр Роттердам Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
EP2517556B2 (en) 2009-07-08 2023-03-22 Kymab Limited Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
KR102004106B1 (ko) 2010-03-31 2019-07-25 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
SMT201900241T1 (it) 2010-06-22 2019-05-10 Regeneron Pharma Topi esprimenti una catena leggera ibrida di immunoglobulina con una regione variabile umana
DK2597945T3 (da) 2010-07-26 2020-09-21 Trianni Inc Transgene dyr og fremgangsmåder til anvendelse deraf
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
RS55495B1 (sr) 2010-08-02 2017-04-28 Regeneron Pharma Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
SI3865581T1 (sl) 2011-08-05 2024-12-31 Regeneron Pharmaceuticals, Inc. Miši s humanizirano univerzalno lahko verigo
CA2846319A1 (en) 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
JP2014531452A (ja) * 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
PL2793567T3 (pl) * 2011-12-20 2019-09-30 Regeneron Pharmaceuticals, Inc. Myszy z humanizowanym łańcuchem lekkim
HUE045537T2 (hu) 2012-03-16 2019-12-30 Regeneron Pharma PH-érzékeny immunglobulin-szekvenciákat expresszáló rágcsálók
AU2013204581B2 (en) 2012-03-16 2015-06-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
RU2644684C2 (ru) 2012-03-16 2018-02-13 Регенерон Фармасьютикалз, Инк. Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
JP2015512635A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
WO2014130690A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
EP4545567A3 (en) * 2013-03-13 2025-08-13 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9980470B2 (en) 2013-03-14 2018-05-29 Erasmus University Medical Center Antibody production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
LT3046412T (lt) * 2013-09-18 2019-07-25 Regeneron Pharmaceuticals, Inc. Histidino pakeitimus lengvoje grandinėje turintys antikūnai ir genetiškai modifikuoti gyvūnai, išskyrus žmogų, išvesti jų gamybai
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
WO2015103999A1 (en) * 2014-01-10 2015-07-16 Hung Alfur Fu-Hsin Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
ES2872475T3 (es) 2014-03-21 2021-11-02 Regeneron Pharma Animales no humanos que producen proteínas de unión de dominio único
WO2015143406A2 (en) * 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
MY181896A (en) 2014-06-06 2021-01-12 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
JP2017529841A (ja) 2014-09-19 2017-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ抗原受容体
JP2017531642A (ja) 2014-10-03 2017-10-26 マサチューセッツ インスティテュート オブ テクノロジー エボラ糖タンパク質に結合する抗体およびその使用
US10100129B2 (en) 2014-11-21 2018-10-16 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
PL3233912T3 (pl) 2014-12-19 2021-12-27 Regenesance B.V. Przeciwciała, które wiążą ludzkie c6 oraz ich zastosowania
EP3237448A1 (en) 2014-12-23 2017-11-01 Bristol-Myers Squibb Company Antibodies to tigit
ES2721775T3 (es) 2015-02-05 2019-08-05 Basf Se Central solar con un primer circuito de portador de calor y un segundo circuito de portador de calor
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
HUE061253T2 (hu) 2015-05-29 2023-06-28 Bristol Myers Squibb Co Antitestek OX40 ellen és azok felhasználásai
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
JP6983776B2 (ja) 2015-11-19 2021-12-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
US11053288B2 (en) 2016-02-04 2021-07-06 Trianni, Inc. Enhanced production of immunoglobulins
KR20220033522A (ko) 2016-03-04 2022-03-16 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
EP4406550A3 (en) 2016-03-04 2024-10-16 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
EP3455256A1 (en) 2016-05-09 2019-03-20 Bristol-Myers Squibb Company Tl1a antibodies and uses thereof
AU2017268458B2 (en) 2016-05-20 2022-07-21 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide RNAS
EP3462853B1 (en) 2016-06-03 2023-03-01 Regeneron Pharmaceuticals, Inc. Rodents expressing exogenous terminal deoxynucleotidyltransferase
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US20170371963A1 (en) * 2016-06-27 2017-12-28 Facebook, Inc. Systems and methods for identifying matching content
EP4512829A3 (en) 2016-07-14 2025-06-11 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
CR20210094A (es) 2016-10-13 2021-03-31 Massachusetts Inst Technology ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193)
US12063913B2 (en) 2016-10-31 2024-08-20 National University Corporation Tottori University Human antibody-producing non-human animal and method for preparing human antibodies using same
PL3766343T3 (pl) 2016-11-04 2022-09-26 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż człowiek posiadające zmodyfikowany sposobami inżynierii locus łańcucha lekkiego lambda immunoglobuliny
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
PT3720279T (pt) * 2017-12-05 2022-10-06 Regeneron Pharma Ratinhos tendo uma cadeia leve lambda de imunoglobulina manipulada e seus usos
CN120192415A (zh) 2018-01-12 2025-06-24 百时美施贵宝公司 抗tim3抗体及其用途
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
HUE070158T2 (hu) 2018-03-24 2025-05-28 Regeneron Pharma Genetikailag módosított egerek vagy patkányok peptid-mhc komplexek elleni terápiás antitestek létrehozásra, ezek elõállítására szolgáló módszerek, valamint alkalmazásuk
AU2019242586B2 (en) 2018-03-26 2025-09-11 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
US11337409B2 (en) 2018-06-08 2022-05-24 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain I
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
CN112969929B (zh) 2018-10-26 2024-06-21 日本汽车能源株式会社 电池控制装置
SG11202104969RA (en) 2018-11-16 2021-06-29 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
KR20230128134A (ko) 2019-01-22 2023-09-01 브리스톨-마이어스 스큅 컴퍼니 Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
AU2020226865A1 (en) 2019-02-22 2021-07-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
CA3136478A1 (en) * 2019-06-05 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
CN114554841B (zh) * 2019-07-01 2024-06-11 特里安尼公司 转基因哺乳动物及其使用方法
EP4069722A1 (en) 2019-12-02 2022-10-12 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
JP2023541216A (ja) * 2020-06-25 2023-09-29 ヒューマブ カンパニー リミテッド ヘテロ接合型トランスジェニック動物
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
CN116848254A (zh) 2020-12-16 2023-10-03 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
EP4559939A3 (en) 2020-12-23 2025-09-24 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses therof
US12371487B2 (en) 2020-12-23 2025-07-29 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
WO2023199655A1 (ja) 2022-04-13 2023-10-19 日本精工株式会社 軸受装置の状態の検出方法、検出装置、およびプログラム
USD999969S1 (en) * 2022-04-29 2023-09-26 Shenzhen Intellirocks Tech. Co., Ltd. Lamp
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
TW202509069A (zh) 2023-05-04 2025-03-01 美商諾瓦森塔股份有限公司 抗cd161抗體及其使用方法
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5658727A (en) 1991-04-10 1997-08-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
EP2305027B1 (en) * 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) * 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
MXPA03004793A (es) * 2000-11-30 2004-12-03 Medarex Inc Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
CA2446968C (en) * 2001-05-11 2012-07-03 Kirin Beer Kabushiki Kaisha Human artificial chromosome containing human antibody .lambda. light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
CN103205436B (zh) * 2003-07-15 2016-05-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
CN102942631B (zh) * 2004-08-05 2015-03-25 健泰科生物技术公司 人源化抗c-met拮抗剂
PL1802193T3 (pl) 2004-10-19 2014-09-30 Regeneron Pharma Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej
KR100971497B1 (ko) * 2004-12-29 2010-07-21 주식회사유한양행 인간 종양괴사인자-알파에 특이적으로 결합하는 인간화항체
EP2003960B1 (en) 2006-03-31 2015-06-10 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
JP2010501165A (ja) * 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド 抗体の作製方法
DK2769992T3 (da) 2006-10-02 2021-03-22 Regeneron Pharma Humane antistoffer med høj affinitet for human IL-4-receptor
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
CA2721231C (en) * 2008-04-14 2015-10-06 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
EP2288623B1 (en) * 2008-05-23 2013-07-10 Ablexis, LLC Method of generating single vl domain antibodies in transgenic animals
DK2346994T3 (da) 2008-09-30 2022-02-28 Ablexis Llc Knock-in-mus til fremstilling af kimære antistoffer
RU2011129459A (ru) * 2008-12-18 2013-01-27 Эрасмус Юниверсити Медикал Сентр Роттердам Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение
EP2517556B2 (en) * 2009-07-08 2023-03-22 Kymab Limited Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
WO2011097603A1 (en) * 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
SG186238A1 (en) 2010-06-17 2013-01-30 Kymab Ltd Animal models and therapeutic molecules
SMT201900241T1 (it) 2010-06-22 2019-05-10 Regeneron Pharma Topi esprimenti una catena leggera ibrida di immunoglobulina con una regione variabile umana

Also Published As

Publication number Publication date
MY195214A (en) 2023-01-11
KR102059909B1 (ko) 2019-12-27
CN104404050A (zh) 2015-03-11
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
JP2018201527A (ja) 2018-12-27
EP2905338A1 (en) 2015-08-12
US20120073004A1 (en) 2012-03-22
WO2011163311A1 (en) 2011-12-29
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
MX2022002117A (es) 2022-03-17
US20150246977A1 (en) 2015-09-03
MX348942B (es) 2017-07-04
HRP20171666T1 (hr) 2017-12-15
SMT201900241T1 (it) 2019-05-10
US20190153384A1 (en) 2019-05-23
NZ707198A (en) 2016-04-29
ES2570131T3 (es) 2016-05-17
DK2480675T3 (en) 2016-08-01
JP2023133554A (ja) 2023-09-22
HUE030285T2 (en) 2017-05-29
EP3205726A1 (en) 2017-08-16
US20170258059A1 (en) 2017-09-14
CN104342455B (zh) 2017-05-31
JP2025027148A (ja) 2025-02-26
DK2568049T3 (en) 2016-08-01
US9206262B2 (en) 2015-12-08
CY1122877T1 (el) 2021-05-05
US9035128B2 (en) 2015-05-19
BR122020013427B1 (pt) 2021-08-03
EP2905338B1 (en) 2017-08-02
IL291301B1 (en) 2023-03-01
CY1118126T1 (el) 2017-06-28
AU2011271043A1 (en) 2013-01-31
JP2018201528A (ja) 2018-12-27
US20150089680A1 (en) 2015-03-26
US9334333B2 (en) 2016-05-10
US9399683B2 (en) 2016-07-26
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
MX347322B (es) 2017-04-21
SMT201600213B (it) 2016-08-31
PL2905338T3 (pl) 2018-01-31
SG186390A1 (en) 2013-01-30
JP6009441B2 (ja) 2016-10-19
KR20200143511A (ko) 2020-12-23
NZ707200A (en) 2016-04-29
KR102211911B1 (ko) 2021-02-05
JP5988969B2 (ja) 2016-09-07
JP6341972B2 (ja) 2018-06-13
JP2016010415A (ja) 2016-01-21
US9540452B2 (en) 2017-01-10
HK1183321A1 (en) 2013-12-20
MY157477A (en) 2016-06-15
CN103068993B (zh) 2016-01-06
IL223720A (en) 2017-05-29
KR20180135997A (ko) 2018-12-21
IL259965B (en) 2019-02-28
EP2568049A1 (en) 2013-03-13
KR20210073609A (ko) 2021-06-18
WO2011163314A1 (en) 2011-12-29
HUE036597T2 (hu) 2018-07-30
KR102118565B1 (ko) 2020-06-03
JP2019033765A (ja) 2019-03-07
SI2480675T1 (sl) 2016-08-31
US9844212B2 (en) 2017-12-19
JP7236409B2 (ja) 2023-03-09
BR112012032991A2 (pt) 2015-10-06
EP2480675A1 (en) 2012-08-01
US20150176002A1 (en) 2015-06-25
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
BR112012032991B1 (pt) 2021-08-10
IL300712B2 (en) 2024-11-01
KR102320944B1 (ko) 2021-11-04
SI3034608T1 (sl) 2019-06-28
MY194456A (en) 2022-11-30
KR20190049932A (ko) 2019-05-09
SG186391A1 (en) 2013-01-30
SG10201504568YA (en) 2015-07-30
KR101934852B1 (ko) 2019-01-04
SG10201504324UA (en) 2015-07-30
US20150246976A1 (en) 2015-09-03
RU2016119423A3 (cg-RX-API-DMAC7.html) 2019-11-19
US20190203171A1 (en) 2019-07-04
ME03386B (me) 2020-01-20
DK2905338T3 (da) 2017-11-06
ME02442B (me) 2016-09-20
US9394373B2 (en) 2016-07-19
JP2013531501A (ja) 2013-08-08
US20150173331A1 (en) 2015-06-25
HUE044001T2 (hu) 2019-09-30
KR101970944B1 (ko) 2019-04-23
US9066502B2 (en) 2015-06-30
CA2804311A1 (en) 2011-12-29
PL2480676T3 (pl) 2016-10-31
EP2480676A1 (en) 2012-08-01
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
SMT201600212B (it) 2016-08-31
RU2724736C2 (ru) 2020-06-25
IL259965A (en) 2018-07-31
IL300712A (en) 2023-04-01
US20150320023A1 (en) 2015-11-12
BR112012033248A2 (pt) 2017-11-28
JP2016010417A (ja) 2016-01-21
ZA201404600B (en) 2015-09-30
KR20190073584A (ko) 2019-06-26
RS54891B1 (sr) 2016-10-31
DK2480676T3 (en) 2016-06-20
SI2905338T1 (sl) 2017-12-29
SI2480676T1 (sl) 2016-10-28
CN103068993A (zh) 2013-04-24
EP2480676B1 (en) 2016-04-06
PT2480676E (pt) 2016-06-09
ZA201506598B (en) 2017-03-29
MX2012015300A (es) 2013-05-01
NZ627119A (en) 2015-05-29
KR101945352B1 (ko) 2019-02-07
US9163092B2 (en) 2015-10-20
EP3456832A1 (en) 2019-03-20
KR20190014578A (ko) 2019-02-12
IL244450A (en) 2017-11-30
IL282872A (en) 2021-06-30
US20240327785A1 (en) 2024-10-03
JP6963542B2 (ja) 2021-11-10
HRP20160497T1 (hr) 2016-07-15
EP3034608B1 (en) 2019-01-30
KR20210013376A (ko) 2021-02-03
IL247386A (en) 2017-07-31
HRP20160865T1 (hr) 2016-10-07
HK1170766A1 (zh) 2013-03-08
US20170107484A1 (en) 2017-04-20
KR102193823B1 (ko) 2020-12-22
PT3034608T (pt) 2019-05-28
SMT201600229B (cg-RX-API-DMAC7.html) 2016-08-31
KR102462042B1 (ko) 2022-11-03
KR101991234B1 (ko) 2019-06-20
DK3034608T3 (da) 2019-05-06
US9226484B2 (en) 2016-01-05
AU2011271046A1 (en) 2013-01-31
HRP20160794T1 (hr) 2016-08-12
KR20190142436A (ko) 2019-12-26
NZ605758A (en) 2014-08-29
EP2480675B1 (en) 2016-04-06
HRP20190807T1 (hr) 2019-08-23
CN104404050B (zh) 2018-06-08
IL291301B2 (en) 2023-07-01
RU2013102595A (ru) 2014-07-27
US9850462B2 (en) 2017-12-26
RU2601297C2 (ru) 2016-10-27
JP2020128440A (ja) 2020-08-27
US9006511B2 (en) 2015-04-14
US9012717B2 (en) 2015-04-21
ME02440B (me) 2016-09-20
AU2011271043B2 (en) 2015-10-01
MY195217A (en) 2023-01-11
RU2590594C2 (ru) 2016-07-10
KR102001430B1 (ko) 2019-07-18
JP6073441B2 (ja) 2017-02-01
US20150173332A1 (en) 2015-06-25
MX2012015298A (es) 2013-05-01
US9206263B2 (en) 2015-12-08
CN103068994A (zh) 2013-04-24
KR20180135996A (ko) 2018-12-21
RS55042B1 (sr) 2016-12-30
US9206261B2 (en) 2015-12-08
CY1117537T1 (el) 2017-04-26
ES2646052T3 (es) 2017-12-11
ZA201404601B (en) 2016-02-24
KR20210134424A (ko) 2021-11-09
ZA201300063B (en) 2014-09-25
CA2804311C (en) 2017-09-12
AU2011271043A8 (en) 2016-01-21
ZA201300062B (en) 2014-09-25
IL255179B (en) 2018-06-28
AU2011271043A9 (en) 2015-10-01
ME02902B (me) 2018-04-20
JP2018023403A (ja) 2018-02-15
BR112012032991A8 (pt) 2020-09-29
TR201905992T4 (tr) 2019-05-21
PL2568049T3 (pl) 2017-03-31
CY1117692T1 (el) 2017-05-17
RS58736B1 (sr) 2019-06-28
CA2803864A1 (en) 2011-12-29
RS55037B1 (sr) 2016-12-30
SMT201700506T1 (it) 2018-01-11
US20160057979A1 (en) 2016-03-03
US20120070861A1 (en) 2012-03-22
HK1226766A1 (en) 2017-10-06
IL300712B1 (en) 2024-07-01
MX336344B (es) 2016-01-15
IL291301A (en) 2022-05-01
CA2803864C (en) 2017-05-16
US20140137275A1 (en) 2014-05-15
SI2568049T1 (sl) 2016-10-28
CN104342455A (zh) 2015-02-11
MY165287A (en) 2018-03-21
JP2017012204A (ja) 2017-01-19
KR102506001B1 (ko) 2023-03-07
JP2017006152A (ja) 2017-01-12
RU2013102596A (ru) 2014-07-27
IL255179A0 (en) 2017-12-31
EP3034608A1 (en) 2016-06-22
IL269078A (en) 2019-11-28
EP2568049B1 (en) 2016-04-13
US20130323790A1 (en) 2013-12-05
JP6545773B2 (ja) 2019-07-17
RS56589B1 (sr) 2018-02-28
AU2011271046B2 (en) 2015-10-01
US20160060359A1 (en) 2016-03-03
JP2021061863A (ja) 2021-04-22
IL313063A (en) 2024-07-01
JP2013532974A (ja) 2013-08-22
JP2022066449A (ja) 2022-04-28
KR20130027555A (ko) 2013-03-15
IL223719A (en) 2016-10-31
JP2020062061A (ja) 2020-04-23
LT2905338T (lt) 2017-12-27
US9029628B2 (en) 2015-05-12
ES2575223T3 (es) 2016-06-27
IL264634B (en) 2019-09-26
JP6243384B2 (ja) 2017-12-06
CN103068994B (zh) 2016-01-20
CY1119478T1 (el) 2018-03-07
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
KR20200064166A (ko) 2020-06-05
MY195212A (en) 2023-01-11
US20130326647A1 (en) 2013-12-05
ES2576928T3 (es) 2016-07-12
KR20220150430A (ko) 2022-11-10
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
US20200239837A1 (en) 2020-07-30
HUE029691T2 (en) 2017-03-28
HUE029692T2 (en) 2017-03-28
MX347318B (es) 2017-04-21
PL3034608T3 (pl) 2019-08-30
KR20230036157A (ko) 2023-03-14
IL244450A0 (en) 2016-04-21
PT2480675T (pt) 2016-07-11
US20150351371A1 (en) 2015-12-10
NZ605751A (en) 2014-10-31
NO2905338T3 (cg-RX-API-DMAC7.html) 2017-12-30
US9150662B2 (en) 2015-10-06
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
ME02444B (me) 2016-09-20
EP2905338B8 (en) 2018-01-24
LT2480675T (lt) 2016-10-10

Similar Documents

Publication Publication Date Title
NZ626979A (en) Mice expressing a light chain with human lambda variable and mouse constant regions
NZ601679A (en) Common light chain mouse
Arrigo Human small heat shock proteins: protein interactomes of homo-and hetero-oligomeric complexes: an update
NZ703689A (en) Humanized non-human animals with restricted immunoglobulin heavy chain loci
CY1121638T1 (el) Ποντικοι με εξανθρωπισμενη ελαφρια αλυσιδα
CA2853731C (en) Humanized il-6 and il-6 receptor
FI2738258T4 (fi) ADAM6-hiiriä
NZ704957A (en) Genetically modified non-human animals and methods of use thereof
MY156743A (en) Humanized fc?r mice
SG177025A1 (en) Hepatitis b virus specific antibody and uses thereof
EA200900568A1 (ru) Модифицированные цианобактерии
MX391010B (es) Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina
PH12012502575A1 (en) Plants having enhanced yield-related traits and a method for making the same
WO2014068437A3 (en) Enhanced acyltransferase polynucleotides, polypeptides, and methods of use
MX2015005271A (es) Polinucleotidos, polipeptidos y metodos de suso novedoso de aciltransferasa.
CU20170036A7 (es) Mezclas que comprenden una pluralidad de polipéptidos con actividad degradante de biomasa y métodos para producir las mismas
Brown Mallee Emu-wren (Stipiturus mallee): multi-scale habitat requirements and population structure
Petrov Kostov A mapping defined by the Schur-Szegő composition
EA201491860A1 (ru) Растения solanum lycopersicum c нетрансгенными изменениями в гене rin
Vinci et al. Chemerin As a New Potential Player in the Immunoregulatory Activity of Mesenchymal Stromal Cells
Wisser et al. Projected changes in daily precipitation in West Africa with implications for crop production around 2050 in CORDEX simulations
Pietrella Empirical regional models for the short-term forecast of M3000F2 during not quiet geomagnetic conditions over Europe
WU Cloning of allanase gene from garlic bulb and its expression in Pichia pastoris
EP4041305A4 (en) Use of entpd3 for identification, isolation, and enhancing mature stem cell derived insulin-producing cells
GARCIA et al. Designing entrepreneurship. Creating enterprise through design culture

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 JUN 2018 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20151224

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUN 2019 BY ANAQUA SERVICES

Effective date: 20180522

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUN 2020 BY ANAQUA SERVICES

Effective date: 20190521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUN 2021 BY ANAQUA SERVICES

Effective date: 20200520

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUN 2022 BY ANAQUA SERVICES

Effective date: 20210519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUN 2023 BY ANAQUA SERVICES

Effective date: 20220523

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUN 2024 BY ANAQUA SERVICES

Effective date: 20230524

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUN 2025 BY ANAQUA SERVICES

Effective date: 20240521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUN 2026 BY ANAQUA SERVICES

Effective date: 20250520